In sum, we here show that integrin αVβ3 transduces pro-survival signals into TCL nuclei, suggesting a novel mechanism for the endocrine modulation of TCL pathophysiology. Targeting this mechanism could constitute an effective and potentially low-toxicity chemotherapy-free treatment for TCL patients.
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INTRODUCTION:
T-cell lymphomas (TCL) are a molecular and clinical heterogeneous group of lymphoproliferative disorders broadly classified according to their origin into T-cell lymphoblastic lymphoma (from precursor T cells) and peripheral T-cell lymphomas -PTCL-(from mature T cells). 1 Amongst the later, the most common varieties are the nodal types including the PTCL not otherwise specified (PTCL-NOS), the anaplastic large cell lymphoma (ALCL), and the angioimmunoblastic T-cell lymphoma (AITL).
Although some subtypes may follow a more benign prolonged course, the vast majority of PTCL patients have poor prognoses due to the combination of an aggressive clinical course and the lack of specific treatments originally designed for B-cell lymphomas. [2] [3] [4] The cellular microenvironment plays an essential role in the pathogenesis and progression of lymphomas. 5, 6 The interaction of lymphoma cells with ligand molecules in the extracellular matrix (ECM) is responsible for the colonization of specific anatomical sites as well as for lymphoma cell survival and aggressiveness. 6 The principal ECM receptors are integrins that mediate cell attachment to other cells and to the ECM. Engagement of integrins by ECM ligands induces a variety of intracellular signals that regulate migration, differentiation, proliferation and apoptosis. Altered integrin expression or signaling is frequently associated with lymphoma cell invasion and growth. 7 Integrins are α/β heterodimers with different ligand specificity. The integrin αVβ3, expressed in malignant cells, osteoclasts and dividing endothelial and vascular smooth muscle cells 8 , binds ECM components (e.g. vitronectin) and is also the membrane receptor for thyroid hormones (TH). [9] [10] [11] Therefore, THs exerts their biological actions through simultaneous binding of nuclear receptors and integrin αVβ3. TH-induced activation of integrin αVβ3 triggers a signaling cascade that modulates the transcription of a set of genes that will complement the nuclear-initiated program. [10] [11] [12] We recently demonstrated that physiological levels of THs can stimulate the proliferation of murine T-cell lymphomas through complementary intracellular pathways involving nuclear and membrane receptors, ultimately leading to PKC, ERK 1/2 and NF-κB activation. 13, 14 In this context, a hypothyroid state would be beneficial for TCL patients; however, this strategy is associated with potentially harmful effects that preclude its clinical application. We hypothesized that targeting integrin αVβ3 could help to overcome this limitation; however, the mechanistic contributions of integrin αVβ3 to human TCL survival are unknown.
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METHODS

T-cell
Additional methods are described in Supplementary Material.
RESULTS:
T-cell lymphomas express canonical and non-canonical thyroid hormone receptors. We demonstrated that THs induce murine T-cell lymphoma proliferation in We determined the functionality of TH receptors by exposing CUTLL1 cells to physiologic concentrations of free and agarose-coupled (cell impermeable) T3 and T4.
Agarose-bound THs bind exclusively to the membrane receptor without binding to nuclear receptors 9 , providing a discriminatory tool to activate exclusively integrin αvβ3.
We found that free and TH-AG hormones significantly increased the proliferation of CUTLL1 cells ( Figure 1C) . A higher effect was obtained by the combination at physiological dose and ratio of both T3 and T4 or T3-AG and T4-AG compared to each hormone alone ( Figure 1C) . A similar proliferative effect was found across immature and mature TCL cell lines that showed an increase in proliferative activity ranging from 30% to 50% ( Figure 1D ).
To further characterize this effect, we measured DNA synthesis and expression of molecular markers of cell cycle progression in representative immature (CUTLL1) and mature (HuT78 and OCI-Ly12) cells. We found that TH and TH-AG significantly increased DNA synthesis ( Figure 1E ). This was associated with a cell cycle progression-dependent induction of cyclins upon hormone addition to arrested cells. An initial increase of D-type cyclins required for the progression from G0 to G1, was followed by subsequent increase in cyclin E2 (G1 to S, and S phase) and cyclin B1 (G2 to M) in CUTLL1 cells exposed to either TH or TH-AG ( Figure 1F 
TH-activated integrin αvβ3 dimer sustains T-cell lymphoma proliferation.
Physiological levels of THs increase the proliferation of TCLs through membrane and nuclear receptors. However, targeting integrin αvβ3, instead of thyroid hormone production or the ubiquitous THRA, would constitute a more feasible anti-lymphoma strategy to translate to patients. The TH binding site on integrin αvβ3 is in close proximity to the RGD recognition site, 9, 11 accordingly, a competing RGD peptide completely abrogated the effect of TH-AG on cell proliferation and decreased a significant fraction of the pro-survival effect of free TH (Figure 2A ). In absence of integrin αvβ3 ligand, the RGD peptide alone had no effect on cell proliferation ( Figure   For Figure 3D ). This data indicates that THdependent regulation of these genes is due to the activation of αvβ3 and further inhibition of this integrin abrogates this signaling event.
Pathway analysis and our previous findings in murine TCL models 18 suggest that NF-κB mediates downstream of the TH-activated αvβ3 integrin signaling. We now confirmed that in human TCLs TH also induced the activation and therefore nuclear translocation of NF-κB ( Figure 3E) . Moreover, administration of the specific NF-κB inhibitor BAY-11-7082 significantly abrogated the up-regulation of VEGFB and IL4 on both immature (CUTLL1) and mature (HuT78 and OCI-Ly12) TCL cell lines ( Figure   3F ). BAY-11-7082 alone was unable to decrease VEGFB or IL4 ( Figure 3E ). This 
To further characterize the paracrine consequences of TH-induced integrin-dependent VEGF up-regulation, we analyzed the effect of a conditioned medium from CUTLL1, HuT78 or OCI-Ly12 cells treated with TH-AG on the migration of endothelial cells, a VEGF-dependent effect. Conditioned medium was placed in the lower compartment of a dual chamber device separated from the upper compartment containing HMEC1 endothelial cells by a polycarbonate porous membrane. We then quantified the HMEC1 endothelial cells that migrated to the lower compartment and found a significant increase in the number of endothelial cells that migrated to the lower compartment when TH-AG treated TCL conditioned media was used (Figure 4E,F) . To confirm that this effect was VEGF dependent, we conducted this experiment adding the anti-VEGF antibody Bevacizumab to HMEC1 culture medium. We found that anti-VEGF effectively impaired the HMEC1 migration effect of the conditioned media ( Figure 4F ). There was no toxicity associated with this treatment as determined by body weight and macroscopic examination of mice tissues.
DISCUSSION
Here we showed that physiological concentrations of THs acting through integrin αVβ3
induce angiogenesis and proliferation of immature and mature TLC cells. We characterized the transcriptional program triggered upon activation of the integrin αVβ3
by TH that is ultimately linked to the induction of angiogenic and cell proliferation genes such as VEGF, an NFkB dependent mechanism ( Figure 6F) . Moreover, we found that 25 Transcript analysis of our TCL panel showed undetectable levels of DIO3 and DIO2, and low expression of DIO1 (not shown). Nonetheless, using physiological levels of T3 and T4, we demonstrated that THs are growth factors for TCL. These effects were mediated by free and cell impermeable hormones, and included increments in cell proliferation, metabolism and cell cycle induction and progression.
In the characterization of the programs induced by TH on integrin αvβ3, we found genes related to signaling cascades for proliferation and angiogenesis, such as IL-4, DOK2
and VEGFB that present NF-κB binding sites in their promoter regions. We further confirmed the participation of NF-κB in the signaling cascade triggered upon integrin αvβ3 activation. IL-4 is a proliferative cytokine for PTCL 26 and T-ALL cells, in the later through a mTOR-dependent regulation of cell cycle progression. 27 The adaptor DOK2, frequently overexpressed in ALCL 28 , acts as a common substrate for multiple tyrosine kinases and induces cell migration, in part, by interacting with integrin For
The proliferative action of THs was abrogated by knockdown of αV and/or β3 integrins and by an integrin αVβ3-selective RGD peptidomimetic compound, thus indicating that the heterodimeric integrin αVβ3 is sufficient to transduce the proliferative effects of THs. 
